20 patents currently held
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Sep 2034. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Sep 2034
Next term end
11
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Apr 2035 · High confidence
Also notable
Ends Jan 2036 · High confidence
Also notable
Ends Sep 2037 · High confidence
Modified J-Chain
US 11,555,075
Cited by 15 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2035. A terminal disclaimer caps this term to an earlier patent's.
Multimeric Death Domain-Containing RECEPTOR-5 (DR5) Antibodies and Uses Thereof
US 10,689,449
Cited by 29 later US patents, top 10% of utility patents granted in 2020 in our data. Protection runs to 2036. A terminal disclaimer caps this term to an earlier patent's.
ANTI-PD-L1 Antibodies
US 10,954,302
Cited by 22 later US patents, top 10% of utility patents granted in 2021 in our data. Protection runs to 2037.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 16, 2027The maintenance fee for Constant Chain Modified Bispecific, Penta- and Hexavalent Ig-M Antibodies (US 10,351,631) comes due Jan 16, 2027. Unpaid by Jul 16, 2027, it lapses early.
- 1 fee due Mar 3, 2027The maintenance fee for Modified J-Chain (US 10,400,038) comes due Mar 3, 2027. Unpaid by Sep 3, 2027, it lapses early.
- 1 fee due Aug 25, 2027The maintenance fee for Multi-Valent Human Immunodeficiency Virus Antigen Binding Molecules and Uses Thereof (US 10,570,191) comes due Aug 25, 2027. Unpaid by Feb 25, 2028, it lapses early.
- 1 fee due Sep 30, 2027The maintenance fee for Multi-Valent Hepatitis B Virus Antigen Binding Molecules and Uses Thereof (US 10,604,559) comes due Sep 30, 2027. Unpaid by Mar 31, 2028, it lapses early.
- 1 fee due Oct 14, 2027The maintenance fee for Binding Molecules with Modified J-Chain (US 10,618,978) comes due Oct 14, 2027. Unpaid by Apr 14, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The 5 largest of its 11 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Modified J-Chain | 4 in force | to Apr 2035 |
| Binding Molecules with Modified J-Chain | 3 in force | to Sep 2037 |
| Tumor Necrosis Factor (TNF) Superfamily Receptor Igm Antibodies and Uses Thereof | 3 in force | to Jan 2036 |
| IgM Fc AND J-CHAIN MUTATIONS THAT AFFECT IgM SERUM HALF-LIFE | 2 in force | to Mar 2039 |
| Multi-Valent Hepatitis B Virus Antigen Binding Molecules and Uses Thereof | 2 in force | to Mar 2036 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,351,631 | Constant Chain Modified Bispecific, Penta- and Hexavalent Ig-M Antibodies In force · High confidence | In force | High confidence | |
| US 9,951,134 | Modified J-Chain In force · High confidence | In force | High confidence | |
| US 10,400,038 | Modified J-Chain In force · High confidence | In force | High confidence | |
| US 10,975,147 | Modified J-Chain In force · High confidence | In force | High confidence | |
| US 11,555,075 | Modified J-Chain In force · High confidence | In force | High confidence | |
| US 11,639,389 | Binding Molecules with Modified J-Chain In force · High confidence | In force | High confidence | |
| US 9,938,347 | Tumor Necrosis Factor (TNF) Superfamily Receptor Igm Antibodies and Uses Thereof In force · High confidence | In force | High confidence | |
| US 10,689,449 | Multimeric Death Domain-Containing RECEPTOR-5 (DR5) Antibodies and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,578,131 | Polynucleotides Encoding Death Domain-Containing RECEPTOR-5 (DR5) Binding Molecules In force · High confidence | In force | High confidence | |
| US 10,787,520 | Multimeric Bispecific Binding Molecules Specific for CD20 and CD3 In force · High confidence | In force | High confidence |
Also on record, not counted in the 20: 2 patents in force now held by others · 3 patents ended · 4 applications pending · 29 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.